Abstract
The medicinal chemistry and pharmacology of the four subtypes of adenosine receptors (ARs) and the eight subtypes of P2Y receptors (P2YRs, activated by a range of purine and pyrimidine mono-and dinucleotides) has recently advanced significantly leading to selective ligands. X-ray crystallographic structures of both agonist-and antagonistbound forms of the A 2A AR have provided unprecedented three-dimensional detail concerning molecular recognition in the binding site and the conformational changes in receptor activation. It is apparent that this ubiquitous cell signaling system has implications for understanding and treating many diseases. ATP and other nucleotides are readily released from intracellular sources under conditions of injury and organ stress, such as hypoxia, ischemia, or mechanical stress, and through channels and vesicular release. Adenosine may be generated extracellularly or by cellular release. Therefore, depending on pathophysiological factors, in a given tissue, there is often a tonic activation of one or more of the ARs or P2YRs that can be modulated by exogenous agents for a beneficial effect. Thus, this field has provided fertile ground for pharmaceutical development, leading to clinical trials of selective receptor ligands as imaging agents or for conditions including cardiac arrhythmias, ischemia/reperfusion injury, diabetes, pain, thrombosis, Parkinson's disease, rheumatoid 
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In some cells, the A 2B AR is dually coupled to G s and G q and consequently elevates phosphoinositides, mobilizes calcium and activates phospholipase C and MAPK [111] [112] [113] [114] [115] . This signaling pathway appears to be important in mast cells, in which A 2A and A 2B ARs have opposing actions. ARs are the site of action of widely consumed alkylxanthines, which act as competitive antagonists. Knockout mice and selective ligands as pharmacological tools (Figs. 1, 2, and 3) are now available for all AR subtypes and for many of the P2Y subtypes (except for P2Y 11 that is absent in the mouse) [4] . Many ligands for these receptors are under consideration for pharmaceutical development.
Processing of ARs and P2YRs in the cell has been studied, including posttranslational modification and trafficking, intracellular localization, and the related phenomena of agonistinduced desensitization, internalization, and degradation [5] [6] [7] . The mechanisms of release, uptake, and degradation of extracellular nucleosides and nucleotides have also been explored [8, 9] . The ubiquitous presence of pharmacologically active endogenous ligands of ARs and P2YRs warrants careful consideration in experimental design.
Structure of adenosine and P2Y receptors
The ARs and the P2YRs share the overall topological structure typical of G protein-coupled receptors (GPCRs) belonging to family A: seven α-helical domains (TM) that cross the cell membrane and are connected by three extracellular (ELs) and three intracellular (IL) loops, the N terminus in the extracellular part and the C terminus in the intracellular part of the receptor. Nevertheless, from comprehensive sequence comparisons and phylogenetic analyses, it is clear that ARs and P2YRs belong to two different groups of the rhodopsin-like family of GPCRs [10] , respectively, the rhodopsin α-group and γ-group of GPCRs [11] .
Within the AR family, the average sequence identity between subtypes of the same species is about 47%, which increases to an average of ∼57% if only the TM domains are considered. The residues in the binding cavity involved in ligand recognition are mostly conserved among the AR subtypes and between species, with the A 3 AR being the most divergent from the other subtypes, as shown in Table 2 . Specific variable amino acids in the binding site are most likely involved in the ligand selectivity or the unique pharmacological behavior of each AR subtype.
For the ARs, structural information has been available since 2008 with the high resolution X-ray structure of the human A 2A AR in complex with the antagonist 4-(2-[7-amino-2-(2-furyl)]1,2,4] triazolo [2,3-a] [1, 3, 5] triazin-5-yl-amino] ethyl)phenol 44 (ZM241385) [12] . The crystal structure of the A 2A AR in its inactive conformation gave insight into the ligand recognition mechanism, showing the key residues involved in the ligand binding and the major interactions anchoring the antagonist to the binding site. Many of the site-directed mutagenesis data previously available for the ARs were structurally explained, and new mutational experiments were guided by the knowledge gained from the A 2A AR structure, helping to further define the ligand binding cavity of this AR [13] .
The antagonist-bound A 2A AR structure has since improved widely the modeling approaches to the ARs, suggesting for example the possible binding modes of agonists to the A 2A AR [13, 14] or aiding the modeling of the other AR subtypes [15] . Before the release of the A 2A AR X-ray structure, other structural templates were used for the modeling of the ARs, as detailed in a recent review by Dal Ben et al. [16] [17] . New structural insights into the activation mechanism and the conformational changes that occur upon agonist binding to the A 2A AR were revealed with the recent release of new crystal structures of the A 2A AR in complex with different agonists, the bulky substituted agonist [18] , the native agonist adenosine 1, and the non-selective adenosine-5′-N-ethyluronamide 3 (NECA) [19] . These new crystal structures lack a coupled G protein, but nevertheless, they are helpful in understanding the function of the ARs, and they will aid the drug design approaches for the AR family, thereby also improving the quality of models for other AR subtypes. The conformational changes upon activation of the A 2A AR resemble those of opsin, but there are other changes more specific to this receptor structure such as a see-saw movement of TM7 [18] . Homology models of A 1 AR and A 3 AR based on the agonist-bound structure of the A 2A AR, were recently proposed with docked agonists in the binding site [15] .
The crystal structures of the A 2A AR revealed a peculiar orientation of the ligand in the binding site of the receptor when compared to the available structures of other GPCRs, e.g., bovine rhodopsin or the β-adrenergic receptors. The binding site for the ligands in the ARs is located near the extracellular portion of the domains TM3, TM5, TM6, and TM7, and the ligands are in a roughly vertical orientation with respect to the plane of the membrane. A crucial residue anchoring the aromatic core of agonists and antagonists in the binding pocket of A 2A AR is Asn6.55 (using the numbering convention of Ballesteros and Weinstein [20] ), a residue conserved among the AR subtypes and also among different species. His6.52, Thr3.36, Ser7.42, and His7.43 play key roles in the binding of the hydrophilic ribose moiety of [1, 55] [1, 42, 55] Table 1 or reference [2] nucleoside agonists, while they are less critical in the binding of antagonists. Residues from the extracellular domain EL2 are also involved in anchoring ligands in the binding pocket. Phe168 in A 2A AR, a residue conserved among the ARs, interacts through a strong π-π stacking with the aromatic core of agonists and antagonists. Glu169, conserved in A 1 AR and A 2B AR but substituted with a hydrophobic valine in human A 3 AR, interacts with both agonist and antagonist H-bond donor groups, i.e., the exocyclic amino group of ZM241385, the exocyclic amino groups of NECA and adenosine, or the urea moiety at the C2 position of UK432097. Trp6.48, the socalled "toggle switch" of GPCR activation, is conserved among the ARs and was found in close proximity to the ligands in the A 2A AR complexes. While the residues surrounding the ligand core in the A 2A AR structure are mostly conserved in the binding pocket of the AR subtypes, other residues are less conserved, and possibly, they might be involved in the selectivity of the receptors for different substituted ligands. Those less conserved residues are located mainly in the most extracellular part of the binding cavity embedding the substitutuent groups projecting from the core of the ligands. For example, Leu267(7.32) in A 2A AR is substituted with a serine in A 1 AR, with a lysine in A 2B AR, and a glutamine in A 3 AR. Met270(7.35) in A 2A AR is a threonine in A 1 AR and a leucine in A 3 AR. Also in EL3, there are some nonconserved residues, such as His264 of A 2A AR, which is substituted with an asparagine in A 2B AR and a glutamate in A 3 AR (Table 2) . Sequence alignments, phylogenetic analysis, and effector coupling of the P2YRs have distinguished two P2YR subfamilies [2, 21] . The P2Y 1 -like family activates the phospholipase C signaling pathway through coupling with G q protein.
P2Y 11 R also couples with G s protein to activate adenylate cyclase. The other family of P2YRs is the P2Y 12 -like family, which couples to G i protein to inhibit the adenylate cyclase pathway [23, 24] . The sequence identity between the two subfamilies is quite low, with only 20% identity between P2Y 1 R and P2Y 12 R, while the sequence identity is higher between the members within the same subfamily, for example, with a 45% identity between P2Y 12 R and P2Y 14 R.
Unlike the ARs, no experimentally determined structural information is yet available for the P2YR family, and so far, the only structural characteristics of the P2YRs have come from structural modeling [21, [25] [26] [27] [28] . Mostly, the modeling of P2YRs has focused on identifying the putative binding site and the analysis of the residues involved in the ligand binding and receptor specificity, with the aim to gain information on the ligand recognition mechanism. Site-directed mutagenesis and structure-activity relationship (SAR) analysis have been used to support and guide the modeling of the P2YRs [29] [30] [31] [32] [33] [34] [35] [36] , which has been used to identify new key residues important for the ligand binding and receptor activation [25, [37] [38] [39] . Several models based on different structural templates have been published for many of the P2YRs. The bovine rhodopsin crystal structure was used to build models for P2Y 1 The putative binding pocket of the P2Y 1 R, suggested by the modeling and supported by the many available mutagenesis data, is located near the extracellular region of TM3, TM6, and TM7. The positively charged residues of P2Y 1 R Arg3.29, Lys6.55, and Arg7.39, conserved among the P2Y 1 -like receptors (Table 3) , appear to be involved in the coordination of the negatively charged phosphate groups of V87 L88 T91 Q92 F171 E172 M180 N184 W247 L250 H251 N254 T270 I274 T277 H278   m_A 1  A66 V87 L88 T91 Q92 F171 E172 M180 N184 W247 L250 H251 N254 I270  I274 T277 H278   r_A 1  A66 V87 L88 T91 Q92 F171 E172 M180 N184 W247 L250 H251 N254 I270  I274 T277 H278   h_A 2A  A63 V84 L85 T88 Q89 F168 E169 M177 N181 W246 L249 H250 N253 M270 I274 S277 H278   m_A 2A A60 V81 L82 T85 Q86 F163 E164 M172 N176 W241 L244 H245 N248 M265 I269 S272 H273  r_A 2A  A60 V81 L82 T85 Q86 F163 E164 M172 N176 W241 L244 H245 N248 M265 I269 S272 H273   h_A 2B  A64 V85 L86 T89 Q90 F173 E174 M182 N186 W247 V250 H251 N254 M272 I276 S279 Residues are denoted in the top row by a numbering convention as described [20] Images displaying the role in ligand binding of amino acids in the binding site of various ARs are found in references [12] [13] [14] [15] [16] [17] [18] [19] 62] nucleotide ligands. Hydrophilic residues in the binding pocket were suggested to surround the ribose moiety of the nucleotides, while hydrophobic residues created a favorable environment for the aromatic nucleoside core of the nucleotides derivatives. Position 6.52 is a histidine residue that is conserved across the P2YRs, and mutagenesis studies on P2Y 1 R, P2Y 2 R, and P2Y 12 R have implicated this residue in ligand recognition [28, 33, 35, 47] . Mutagenesis studies on the P2Y 1 R also showed the crucial role of two disulfide bridges for the correct function of the receptor: a disulfide bridge between TM3 and EL2, conserved among family A GPCRs, and a second disulfide bridge between the N terminus and EL3 [32] . The P2YR models have been improved and refined continually using updated information from studies of their structural biology and mutagenesis. Recent advances in the structural biology of GPCRs have provided alternative templates to the bovine rhodopsin structure as a basis for the homology modeling. For example, the sequence identity between rhodopsin and human P2Y 12 R, the site of action of the active metabolite [37] of the blockbuster antithrombotic Clopidogrel [2] , is only 16% overall and 19% for only the TM regions, while the sequence identity between human P2Y 12 R and the chemokine receptor CXCR4 is 22% overall and 26% for the TM domains. The X-ray structures of the human CXCR4 in its inactive state in complex with a small antagonist and a long peptide were released in late 2010 [48] . A sequence comparison between P2Y 12 R and CXCR4 suggested other structural features of CXCR4 that might be shared by P2Y 12 R, making the crystal structure of CXCR4 a more suitable template than other available GPCR crystal structures for the modeling of P2Y 12 and other P2YRs [49, 50] . A model of P2Y 12 R based on the CXCR4 crystal structure and guided by the mutagenesis data and SAR studies available on the P2Y 12 R was recently published [49] . The homology models of P2Y 2 R and P2Y 4 R based on the CXCR4 crystal structure were used to explain the selectivity of agonists toward these two P2YR subtypes [50] . The modeling studies of P2Y 12 R showed how key residues in the binding pocket in TM6 and TM7, Arg6.55, Lys7.35, and Tyr6.58, were involved in the anchoring of the negatively charged phosphate groups of the nucleotide ligands. Those residues are conserved across the P2Y 12 -like subfamily of P2YRs, as shown in Table 3 . Other hydrophobic or aromatic residues from TM1, TM3, TM6, and TM7 were suggested to form a suitable environment for the aromatic core of nucleotides derivatives, while the ribose moiety was surrounded by hydrophilic residues.
Key ligand tools for studying adenosine and P2Y receptors AR agonists and antagonists Selective agonist and antagonist ligands for each of the four AR subtypes are now available as pharmacological tools. The medicinal chemistry of the A 2B AR is the least developed of the four subtypes, with selective antagonists and a few selective agonists reported only since 2000 [51, 52] . The optimal binding features of AR ligands have also been predicted on the basis of quantitative SAR (QSAR) approaches, such as comparative molecular field analysis (CoMFA) [116] [117] [118] [119] , although the use of X-ray structural data is now able to provide greater insight than earlier approaches. The selective AR ligands now include compounds that are stable in vivo, high affinity radioligands for binding assays or in vivo imaging by positron emission tomography or single photon R110  F113  Y114  Y118  F207  F258  F261  H262  R265  Y268  Y288  K289  R292   P2Y 4  R112  F115  Y116  Y120  F209  F258  F261  H262  R265  Y268  Y288  K289  R292   P2Y 6  R103  F106  Y107  H111  F201  F252  F255  H256  K259  Y262  Y283  K284  R287   P2Y 11  R106  F109  T110  L114  C214  Y261  Y264  H265  R268  N271  Y303  Q304  R307   P2Y 12  S101  F104  Y105  Y109  F198  F249  F252  H253  R256  Y259  K280  E281  L284   P2Y 13  S99  F102  Y103  Y107  F217  F247  F250  H251  R254  Y278  K278  E279  L282   P2Y 14  A98  F101  Y102  Y106  F195  F246  F249  H250  R253  Y256  K277  E278  L281 Residues are denoted in the top row by a numbering convention as described [20] . Residues in bold have been shown using site directed mutagenesis to be important in ligand recognition
Images displaying the role in ligand binding of amino acids in the binding site of various P2YRs are found in references [25-27, 31, 33, 35, 38, 40, 42-47, 49, 50] Residues in the ELs that affect ligand recognition include: D204, E209, and R287 (in P2Y 1 R) [31] ; R177, R180, and R272 (in P2Y 2 R) [31] emission tomography [53] , that bind irreversibly to the receptor affinity probes, fluorescent and other spectroscopic probes, and multivalent conjugates that retain high potency. An overview of SAR is provided below for AR agonists and antagonists.
1. Agonists: The SAR of adenosine derivatives as AR agonists has been well explored [1, 54] , and selective agonists and antagonists for all four subtypes have been reported (Figs. 1 and 2 and affinities of selected compounds listed in Table 1 ). Data on selectivity of AR ligands have been collected [1, 55] . Typically, these agonists are nucleoside derivatives substituted at one or more of the following positions: ribose 5′, adenine C2, and adenine N 6 . Hydrophobic groups substituted at the adenine C2 position (linked by NH or S) often provide selectivity for the A 2A AR (e.g., 16, 18, 20) , and hydrophobic groups substituted at the adenine N 6 position often provide selectivity for the A 1 AR (e.g., [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . An N 6 -(4-aminophenylethyl) derivative, APNEA 4, is a nonselective AR agonist with high affinity for both A 1 and A 3 ARs, and has been used as a radioligand in its [ 125 I] 3-iodo form. In exceptional cases, this selectivity pattern may be altered to display A 2A AR selectivity, as in 17, or with combined modifications, as in 19. Nonnucleoside agonists of the A 1 AR are also known, including the clinical candidate Capadenoson 15 [56] .
The most common ribose modification that enhances AR potency is a small N-alkyl-uronamide at the 5′ position, as in the potent nonselective agonist NECA 3, an Nethyl-uronamide. The presence of an N-ethyl-uronamide is typical of A 2 AR-selective agonists (A 2A : 16, 18, and 19; A 2B : 22), and a N-methyl-uronamide is typical of A 3 AR-selective agonists (23) (24) (25) (26) (27) (28) . The ribose moiety of nucleoside ligands having high AR affinity could also be substituted with a limited set of other modifications [54, 55, [57] [58] [59] [60] , for example: carbocyclics, including a ringconstrained methanocarba (fused cyclopropyl and cyclopentyl rings as in A 3 AR-selective 27 and 28), 4′-thio in place of oxo (68), 2′-methyl (9), 2′-methoxy (12) , and 3′-amino-3′-deoxy (25) . By comparing the AR binding affinities of isomeric bicyclic methanocarba adeonsine analogues that maintain either a North (N), as in 27 and 28, or a South (S) conformation, it was determined that there is a strong preference for the (N) conformation in binding to the A 3 AR. This bicyclic modification of ribose often enhances the affinity, as well as selectivity, at the A 3 AR [54] . The (N)-methanocarba modification is also preferred over the (S)-methanocarba modification at the A 1 AR, but affinity enhancement was not observed. The preference of the (N) over (S) conformation of the ribose moiety was also determined using C methylation at the 2′ and 3′ positions [59] .
It is to be noted that some nucleoside derivatives act as full agonists at certain AR subtypes and antagonists or partial agonists at other subtypes. Typically, the efficacy at the A 3 AR is particularly sensitive to structural modification of the nucleoside derivative. Thus, reducing the flexibility or H-bond donating ability of the ribose moiety, especially around the 5′-amide group, or introducing certain sterically bulky hydrophobic substituents at the N 6 or C2 position tends to lower the relative efficacy at the A 3 AR [61] . Various 8-cycloalkylamino adenosine derivatives or those modified at the ribose hydroxyl positions have reduced efficacy at the A 1 AR or A 2A AR [60] . The introduction of bulky groups at the 5′ position has been shown to reduce efficacy at the A 1 AR [56] . Selective agonists for the A 1 AR [54, 57] include: R-PIA 6, CPA 7 and its more selective 2-chloro analogue CCPA 8, and CHA 11 (all of which have been radiolabeled as tracers for binding experiments); SPA 5 (excluded from crossing the blood brain barrier). CPA, CCPA, and CHA are more selective for the A 1 AR in mouse than in human, in comparison to the A 3 AR. (S)-ENBA 13 displays high A 1 AR selectivity (human, rat) in comparison to both A 2A AR and A 3 AR, but also has reduced water solubility. A 4′-truncated (N)-methanocarba nucleoside containing an N 6 -dicyclopropylmethyl group (not shown) fully activated the A 1 AR with moderate selectivity [15] . CGS21680 16 and DPMA 17 are A 2A AR selective in binding to the rat and mouse A 2A ARs, but in the human, they bind with similar affinity to the A 3 AR. The nonnucleoside 3,5-dicyanopyridine derivative 21 and the nucleoside derivative 22 are moderately A 2B AR selective. A 3 AR-selective agonists typically have combined N 6 and ribose 5′ modications (23) (24) (25) (26) (27) (28) . Introduction of certain bulky groups at the 5′ position of A 1 AR reduced the efficacy in functional assays, to provide partial agonists [57] . N 6 -Benzyl substitution tends to provide greater between-species consistency in A 3 AR binding affinity [61] , while small N 6 -alkyl groups, such as methyl (26) are often more potent at the human A 3 AR than at rat and mouse A 3 ARs. However, N 6 -benzyladenosine derivatives are variable in their A 1 AR binding affinity depending on the substitution pattern, which can reduce A 3 AR selectivity. The product of enzymatic action of adenosine deaminase, inosine, also activates the A 3 AR in the micromolar range [ behaves as an antagonist in functional assays, which is related to the absence of the 5′-hydroxymethyl group that is associated with the conformational change needed to activate the A 3 AR [15] . The in silico screening of chemical libraries of diverse structure by docking to an X-ray structure or even a homology model is now an accepted method of discovering new chemotypes that bind to a given GPCR. Nonnucleotide antagonists of ARs and P2YRs have been discovered in this manner [62] .
P2YRs
Progress in the development of selective agonist and antagonist ligands for P2YRs (Fig. 3 , and potencies of selected compounds listed in Table 1 ) has accelerated in recent years. Detailed SAR analyses are available for activation by nucleotides of most of the P2YRs [2, 63] . One must keep in mind that extracellular nucleotides can be interconverted in situ to different phosphate forms or to the corresponding nucleoside, which may complicate pharmacological studies. In some cases, the addition of an inhibitor of ectonucleotidases or of other enzymes involved in this conversion, or even addition of a purified enzyme, aids in the interpretation of pharmacological data. A challenge is to design P2YR ligands that are stable in vivo. Nevertheless, there are now nucleotide agonists selective for P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 , and P2Y 14 Rs and nucleotide antagonists selective for P2Y 1 and P2Y 12 Rs. The diastereoselectivity of binding of the phosphate groups of nucleotide agonists selective at the P2Y 1 , P2Y 2 , P2Y 4 and P2Y 11 Rs has been characterized [29, 41, 42] . Also, subtype-selective non-nucleotide antagonists have been introduced for P2Y 1 , P2Y 6 , P2Y 11 , P2Y 12 , P2Y 13 , and P2Y 14 Rs. Isolated reports have suggested nonnucleotide antagonists of the P2Y 2 R, but these so far are weakly binding. Chemically diverse library screening is now being applied to the problem of identifying new structural leads for receptor antagonists, e.g., the A 2A AR, P2Y 12 R and P2Y 14 R [49, 62, 64] . A general description of SAR is provided below for each of the P2Y subtypes.
P2Y 1 R One of the earliest potent agonists of the P2Y 1 R identified was 2-MeSADP 72 (Fig. 3a) . However, like the native agonist ADP 70, it also activates the P2Y 12 R and P2Y 13 R. There has been a question about the ability of 5′-triphosphate derivatives such as 2-MeSATP 73 to activate the P2Y 1 R; some studies show it to be an agonist while others demonstrate low efficacy [2] .
The introduction of conformationally restricted (i.e., rigid) ribose substitions has established the favored ribosering conformation for each of the subtypes of the P2Y 1 -like subfamily [38, 43] . Principally, this approach has made use of the methanocarba ring system consisting of fused cyclopropane and cyclopentane, as applied earlier to the ARs, in exploring the biologically active conformations of nucleoside and nucleotide derivatives. Thus, the North (N)-methanocarba analog of 2-MeSADP, i.e., MRS 2365 76 is a selective, high affinity agonist of the P2Y 1 R that does not appreciably activate the other ADP-preferring subtypes, i.e., P2Y 12 and P2Y 13 Rs [65] . The (N)-methanocarba modification is also known to improve the stability of the phosphate esters toward nucleotidases, especially the 5′-monophosphate toward the hydrolytic action of the ectonucleotidase CD73. Borano analogues of the phosphate group have been found in some cases to preserve potency and to enhance selectivity of P2YR agonists, e.g., P2Y 1 R agonists [66] .
Many nucleotide antagonists of the P2Y 1 R have been introduced. Usually, these are adenine nucleotides containing bisphosphate groups, for example, a ribose 3′,5′-bisphosphate moiety. N 6 -methyl 2′-deoxyadenosine bisphosphate derivatives MRS 2179 93 and its 2-chloro analogue MRS 2216 (not shown) are selective P2Y 1 antagonists [38] . In both agonist and antagonist series, only limited substitution of the N 6 position of ADP and other nucleotides, i.e., methyl and ethyl, is tolerated at the P2Y 1 R. The same (N)-conformational constraint of the ribose moiety that enhances P2Y 1 R agonist action also favors potency and selectivity in nucleotide antagonists. For example, the ring-constrained (N)-methanocarba nucleotide bisphosphates MRS 2279 94 and MRS 2500 95 are selective, high affinity antagonists of the P2Y 1 R [67] . Antagonists of the P2Y 1 R of moderate affinity may also be derived from acyclic nucleotides, such as the bisphosphate derivative MRS 2298 (not shown) [67] .
A representative antagonist of the P2Y 1 R discovered through optimization of a high throughput screening hit is a substituted 1-phenyl-3-methyl pyrazol-5-one 110, which has a K i of 90 nM and is orally bioavailable [68] . Other structurally diverse antagonists of the P2Y 1 R have been reported. P2Y 2 and P2Y 4 Rs UTP 79 is a native agonist of both P2Y 2 R and P2Y 4 R. Another native ligand, ATP 71, activates the P2Y 2 R, but at the P2Y 4 R its action is species-dependent, i. e., it acts as an antagonist at the human homologue and agonist at the rat P2Y 4 R. Synthetic UTP analogues with selectivity for the P2Y 2 R have been reported, e.g., UTPγS [69] . MRS 2768 90 (uridine tetraphosphate δ-phenyl ester) is somewhat selective for the P2Y 2 R but is less potent than other P2Y 2 R agonists [70] .
Several weak antagonists of the P2Y 2 R that are uracil derivatives, e.g., AR-C126313 and AR-C 118925 (not shown), have been reported but full pharmacological characterization is still lacking [2] . For lack of better antagonists, the anti-infective drug suramin 102 and the large anthraquinone dye Reactive blue 2 100 (RB2), which is a mixture of isomers, are used as partially selective antagonists of the P2Y 2 R and P2Y 4 R, respectively. It should be noted that suramin and many other weak P2YR antagonists typically display other activities, such as inhibition of ectonucleotidases, which may complicate the interpretation of experiments [2] . P2Y 6 R UDP 78 is the native agonist of the P2Y 6 R, but was recently found to also activate the P2Y 14 R [71] . UDPβS 80, 3-phenacyl UDP (PSB 0474) 84, 5-iodo-UDP (MRS 2693) 85 and dinucleoside triphosphates, such as Up 3 U 91 and INS 48823 (not shown) [2] , have been used as moderately selective agonists of the P2Y 6 R [44] . Probing the conformation of the ribose ring at the P2Y 6 R by molecular modeling and chemical synthesis of ring-constrained analogues has clearly identified the South (S)-conformation as the receptor-preferred conformation at this subtype [43] . Thus, a rigid bicyclic (S)-methanocarba-UDP (not shown) was more potent than UDP, and the corresponding ringconstrained isomer with a (N)-conformation was inactive. The di-isothiocyanate derivative MRS 2578 109 is a noncompetitive P2Y 6 R antagonist that has limited stability in aqueous medium and presumably reacts irreversibly with the receptor. P2Y 11 R ATPγS 75 is usually used as a potent but nonselective P2Y 11 R agonist. Few P2Y 11 R-selective agonists have been reported, but an atypical agonist NF546 104 of the suramin class of antagonists was reported to activate this receptor selectively [72] . However, several reported P2Y 12 R antagonists, such as 2-propylthio-β,γ-dichloromethylene-ATP (AR-C 67085 97), also act as potent P2Y 11 R agonists.
The suramin derivative NF 157 103 is an antagonist of the P2Y 11 R, but it is not selective with respect to the nucleotidegated ion channels P2X 1 R, P2X 2 R, and P2X 3 R. NF340 105 related to suramin is a selective P2Y 11 R antagonist. P2Y 12 R ADP 70 is the native agonist of the P2Y 12 R, and another native ligand, ATP 71, acts as a competitive antagonist. Many nucleotide (96) (97) (98) and non-nucleotide (111) (112) (113) (114) (115) antagonists of the P2Y 12 R have been reported, because of commercial interest. The thienopyridine Clopidgrel 113 is a blockbuster antithrombotic agent, which must be first activated in two steps by cytochrome P450 in the liver to subsequently irreversibly inhibit the P2Y 12 R [2, 37, 70] . The recently approved antithrombotic Prasugrel 114 belongs to this thienopyridine family of P2Y 12 antagonists. Competitive P2Y 12 R antagonists that do not require preactivation are also under development, for example, the antithrombotic nucleotide derivative AR-C 69931MX 98 (Cangrelor). An uncharged nucleoside derivative that binds potently to the P2Y 12 R, AZD 6140 99 (Ticagrelor) was recently approved to reduce cardiovascular death and heart attack in cases of acute coronary syndrome. A major metabolite of 99 that is formed by oxidative loss of the hydroxyethyl side chain also acts as a potent P2Y 12 R antagonist [22] . A sulfonate derivative related to RB2, PSB-0739 101, is a representative nonnucleotide antagonist of the P2Y 12 R that displays high affinity and was used in the characterization of the effects of site directed mutagenesis of the receptor and in molecular modeling [34, 49] . P2Y 13 R ADP 70 is a native agonist of the P2Y 13 R, while ATP 71 at high concentrations is at best a weak partial agonist. The pyridoxal phosphate derivative MRS 2211 108, is a selective antagonist of the P2Y 13 R and related to the nonselective P2 antagonists PPADS 106 and iso-PPADS 107 [73] . However, MRS2211 and other pyridoxal phosphate derivatives also inhibit protein interactions of the 14-3-3 family of intracellular phosphoserine/threonine-recognition proteins [74] . P2Y 14 R UDP-glucose 88, other UDP-sugars and UDP 78 are native agonists of the P2Y 14 R [71] . A synthetic 2-thio analog of UDP-glucose, i.e., MRS 2690 89, is a more potent and selective agonist at the P2Y 14 R. α,β-difluoromethylene-UDP, MRS 2802 86, and the more potent α,β-methylene-2-thio analogue MRS2905 87 are inactive at the P2Y 6 R and fully activate the human P2Y 14 R.
Allosteric modulation of ARs and P2YRs
In addition to orthosteric agonists that bind at the same site on the receptor as the native agonist, allosteric modulators for ARs and P2YRs have been studied. The structure and action of positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs) for ARs and P2YR have been recently reviewed [75] . This includes both heterocyclic derivatives and nucleotide analogues that resemble a native P2Y agonist. Some of the PAMs have no action of their own and require the presence of an agonist, either the endogenous ligand or a synthetic agonist, and other PAMs are allosteric agonists that act in the absence of orthosteric ligands. The SAR of PAMs of the A 1 AR (e.g., the tetrahydrobenzothiophene derivative T-62) and A 3 AR (e.g., the imidazoquinolinamine derivative LUF6000 and the quinoline derivative LUF6096, structures not shown) has been extensively explored. Recently, AEA061 was reported as a PAM of the A 2A AR [76] .
Ligands in the clinic and in current clinical trials
The biological role of adenosine and P2YRs has been extensively explored, contributing to the entry of certain selective ligands on a clinical pathway [54, 70, 77, 78] . Table 4 lists those AR and P2YR ligands in the clinic for therapeutic and diagnostic applications, including those currently in clinical trials for chronic diseases, such as inflammatory, ischemic, and neurodegenerative diseases, and for other conditions.
AR ligands as clinical candidates and approved drugs
Adenosine may be released from intracellular sources or generated by the action of ectonucleootidases on ATP that is released under stress conditions. Therefore, depending on pathophysiological factors, in a given tissue, there is often a tonic activation of one or more of the ARs that can be modulated by exogenous agents. AR agonists are currently in clinical trials for various conditions, including cardiac arrhythmias, neuropathic pain, myocardial perfusion imaging, cardiac ischemia, autoimmune inflammatory diseases, and cancer [57, [79] [80] [81] [82] [83] [84] .
The first AR agonist to be approved was adenosine 1 itself (as Adenocard), used as a rapidly metabolized therapeutic treatment of cardiac arrhythmias, specifically paroxysmal supraventricular tachycardia (PSVT), by slowing atrioventricular (AV) nodal conduction, an A 1 AR effect. Its short half-life upon intravenous infusion (seconds) avoids some side effects, although A 2A AR-related side effects still may occur. Other agonists of the A 1 AR have been in clinical trials for pain and cardiac arrythmias, including atrial fibrillation, supraventricular arrythmias, paroxysmal supraventricular tachycardia, and atrial flutter [54, 57] . CVT-3619 (GS9667, not shown), a partial A 1 AR agonist, has been in clinical trials for type 2 diabetes [54] . Side effects associated with A 1 AR agonists applied to cardioprotective and cardiovascular regeneration may be overcome by using partial A 1 AR agonists such as Capadenoson 15 [85] .
Adenosine (as Adenoscan) is used as a pharmacological stress agent for cardiovascular imaging based on its A 2A ARdependent vasodilatory effect in the coronary artery. Also, more advanced A 2A AR-selective agonists [79] are either already approved for this purpose (CVT-3146, 20) or in clinical trials (ATL-146e, Apadenson, 18). A 2A AR agonists also have anti-inflammatory and anti-ischemic effects, and have been in clinical trials for related conditions, including sickle cell disease by targeting iNKT cells [58, 84] . Selective agonists of A 2A , A 2B or A 3 ARs have been shown to have anti-inflammatory effects due to inhibition of the release of pro-inflammatory cytokines and other mechanisms [80, 86, 87] . This also led to former clinical trials of A 2A AR agonists for the treatment of chronic and neuropathic pain and diabetic foot ulcers. However, an A 2A AR agonist was found ineffective for treating foot ulcers. A 2A AR agonists also show beneficial effects in wound healing, because A 2A and A 2B ARs stimulate granulation tissue formation by inducing new matrix production and angiogenesis [88, 89] . A 2B AR agonists have been proposed for the treatment of hyperlipidemia and atherosclerosis [90] .
A 2A AR antagonists (e.g. 42, 45, 48, and 51) are being developed for treatment of Parkinson's disease (PD) and other disorders of the central nervous system including addiction [79, 91] , and several clinical candidates have been radiolabeled for in vivo imaging [53] . In the striatum, a heterodimer of the A 2A AR and the D2 dopamine receptor is thought to establish the inverse action of dopamine and adenosine agonists; thus, an A 2A AR antagonist would have a net effect similar to a D2 agonist. A 2A AR antagonists could also be of interest in preventing fibrosis in the liver and elsewhere [88] or in the treatment of cancer [92] . A 2B AR antagonists are under consideration for treating inflammatory diseases, diabetes, and asthma [81, 82] , although trials of CVT-6883 55 were unsuccessful.
Native adenosine acting at various AR subtypes has antiischemic activities in multiple organs, for example, a cardioprotective action, either as a preconditioning agent or during ischemia reperfusion. Adenosine and more selective AR agonists, e.g. A 3 AR agonists such as CP532,903 25, have been considered for treating acute myocardial infarction [80] . One of the first actions discovered for A 3 AR agonists administered in vivo was cerebroprotection. Also noted were paradoxical effects in which nM concentrations of A 3 AR agonists prevented apoptosis and high μM concentrations induced apoptosis. The relative lack of cardiovascular side effects of A 3 AR agonists in comparison to other AR agonists is considered an advantage in application to ischemia. The orally active A 3 AR agonist CF101 (IB-MECA) 23 is in clinical trials for rheumatoid arthritis, psoriasis, keratoconjunctivitis sicca (dry eye syndrome), and glaucoma [80] . The closely related CF102 (Cl-IB-MECA) 24 is in clinical trials for advanced hepatocellular carcinoma and for patients with chronic hepatitis C genotype 1.
P2YR ligands as clinical candidates and approved drugs
Although the ARs are a mature field of medicinal chemistry, the P2YRs generally lag behind in the development of selective ligands, radioligands and other affinity probes, imaging agents, and clinical candidates. The most successful application in that area is the use of P2Y 12 R antagonists as antithrombotics, but other disease areas are potentially amenable to treatment using selective P2YR agonists or antagonists [70] . Since some P2Y subtypes have a widespread distribution, there might be substantial side effects, such as those noted to occur in bone [4] . Nucleotides, such as ATP 71 and UTP 79, are readily released from intracellular sources under conditions of injury and organ stress, such as hypoxia, ischemia, or mechanical stress, and through channels and vesicular release. One of the consequences of this release is a proinflammatory effect [2] , for example from ATP that accummulates in asthmatic airways. Consistently, antagonists and other ligands of the P2YRs could serve as therapeutic targets for a variety of conditions, including cardiovascular diseases and inflammatory diseases such as asthma and neurodegeneration [70, 93] . It has been suggested that antagonists of P2Y 2 R, P2Y 6 R, or P2Y 11 R might be beneficial in asthma and inflammatory bowel disease [70] . Beneficial effects of P2 receptor antagonists have been observed in a stroke model [94] . The effects of various P2YR ligands on apoptosis in cell culture and in the central nervous system have been explored [95] [96] [97] [98] , suggesting application to a variety of diseases, from cancer to diabetes to ischemia.
P2YRs are widespread in hematopoietic cells, and therefore the effects of extracellular nucleotides and their antagonists are being studied in the immune/inflammatory system. The platelet expresses two P2YRs, i.e., P2Y 1 R and P2Y 12 R, both of which have to be activated in order for ADP to have a prothrombotic effect [23] . Therefore, blocking either of these receptors produces an antithrombotic effect. P2Y 12 R antagonists, three of which are already approved as agents for acute coronary syndrome and for prevention of secondary thrombotic events, have been described above. The antithrombotic action of MRS 2500 95 by selectively blocking the P2Y 1 R is evident in vivo in the mouse and other species, suggesting this receptor subtype as a clinical target. Furthermore, genetic deletion of the P2Y 1 R is associated with fewer atherosclerotic lesions in ApoE −/− mice. Bone marrow reconstitution has demonstrated the involvement of non-hematopoietic-derived cells, probably the endothelial cells [99] . Several agonists of the P2Y 2 R have been in clinical trials for cystic fibrosis and other pulmonary conditions. Activation of the P2Y 2 R on epithelial cells in the airways and the eye promotes chloride secretion, independently of the genetically defective transporter in cystic fibrosis. However, the P2Y 2 R agonist Up 4 -2′-deoxyC (Denufosol) was denied approval for the treatment of cystic fibrosis due to the failure to reproduce the positive results of the TIGER-1 study in the longer duration TIGER-2 trial. A P2Y 2 R agonist of low selectivity, Up 4 U 92 (Diquafosol), has been approved in Japan but not the U.S. for the treatment of dry eye disease [100] . P2Y 2 R activation has also been shown to protect rat fetal cardiomyocytes against ischemia [101] . P2Y 4 R activation by UTP promotes chloride and water secretion by intestinal epithelial cells, suggesting the use of agonists of this subtype in treating chronic constipation [102] .
Pancreatic islets express both the P2Y 1 R and P2Y 6 R, both of which are coupled to G q and promote insulin release. The use of P2Y 1 R agonists in diabetes has been proposed, and relatively stable nucleotide analogues that activate this subtype have been applied in vivo [69] . Furthermore, agonists of the P2Y 6 R have been shown to have beneficial antiapoptotic effects on pancreatic islets cells in culture, suggesting their possible application to diabetes [95] Endogenous UDP activating the P2Y 6 R is involved in the autocrine potentiation of insulin secretion [103] . However, there are significant side effects of activation of the P2Y 6 R, such as a proinflammatory effect, atherosclerotic plaques, cardiac fibrosis and possibly a loss of bone mass [4, 70, 104] .
P2Y 11 R activation mediates ATP-induced semi-maturation of human monocyte-derived dendritic cells and increases the release of interleukin-8 from human monocyte-derived dendritic cells, suggesting use of ligands of this subtype in immune modulation [72, 105] . Semi-maturation of dendritic cells is characterized by an increased expression of costimulatory molecules with no stimulation of interleukin-12 secretion, leading to a Th2 response or tolerance.
The activation and migration of microglia in the brain are modulated by P2YRs [106, 107] . ADP activating the microglial P2Y 12 R induces a "find-me" signal (to induce migration), and UDP activating the microglial P2Y 6 R induces an "eat-me" signal (to induce phagocytosis). These findings suggest application of P2Y 12 R or P2Y 6 R ligands to neuropathic pain and neurodegenerative diseases. Indeed, intrathecal administration of P2Y 12 R antagonist AR-C69931MX 98 prevented the development of tactile allodynia [106] .
Activation of the P2Y 13 R by ADP promotes reverse cholesterol transport in hepatocytes with the endocytosis of HDL particles [108] . Thus, activation of P2Y 13 R might be a new target for treatment of dyslipidemia and atherosclerosis.
Modulation of the P2Y 14 R has potential for the treatment of immune and inflammatory disorders, pain, asthma, gastric disorders, central nervous system diseases, and glaucoma. Non-nucleotide antagonists of the P2Y 14 R, e.g., 116, and prodrug derivatives to increase their bioavailability have been proposed [64] . Intracellular UDP sugars, many of which would activate the cell-surface P2Y 14 R, are substrates for protein glycosylation, and are released as the proteins are trafficked to the surface [71] , where they may fulfill a cell signaling role. The role of P2Y receptors in stem cell differentiation has been explored; P2Y 4 and P2Y 14 Rs appear to regulate the onset of mesenchymal differentiation, and the downregulation of P2Y 1 and P2Y 2 Rs are markers for early osteogenic differentiation [109] .
Conclusions
There have been significant recent advances in the structural biology of purine receptors and in the medicinal chemistry of selective ligands and their pharmacology. Potent purine and pyrimidine analogues have aided in the characterization of regulation of many physiological and pathophysiological processes. It is apparent that this ubiquitous cell signaling system has implications for understanding and treating many diseases. Thus, this field has provided fertile ground for pharmaceutical development.
